Bachem Holding AGBCHMF 92 Days Payable is 24.58 as of Dec. 2025, which is 15% below its 10-year median of 29.06. GuruFocus rates BCHMF with a GF Score™ of 92/100 and a GF Value™ of $98.22 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 707 Biotechnology companies, Bachem Holding AG ranks worse than 76.8% on this metric.
The historical rank and industry rank for Bachem Holding AG's Days Payable or its related term are showing as below:
BCHMF'
s Days Payable Range Over the Past 10 Years
Min: 19.59 Med: 29.06 Max: 44.04
Current: 36.09
During the past 13 years, Bachem Holding AG's highest Days Payable was 44.04. The lowest was 19.59. And the median was 29.06.
BCHMF's Days Payable is ranked worse than 76.8% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs BCHMF: 36.09
Bachem Holding AG's Days Payable
declined
from Dec. 2024 (42.91) to Dec. 2025 (24.58).
It may suggest that Bachem Holding AGaccelerated paying its suppliers.
Bachem Holding AG Days Payable Related Terms
Bachem Holding AG Days Payable Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Bachem Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bachem Holding AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a Days Payable of 24.58 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bachem Holding AG and its competitors. This is 15% below median its historical median of 29.06. Over the past decade, Bachem Holding AG's Days Payable has ranged from 19.59 to 44.04. According to the industry distribution chart, Bachem Holding AG ranks #543 out of 707 companies in the Biotechnology industry, placing it in the top 76.8%.
Is Bachem Holding AG's Days Payable too high?
Bachem Holding AG's current Days Payable of 24.58 is 15% below median its 10-year median of 29.06. Over the past 10 years, this metric has ranged from a low of 19.59 to a high of 44.04. The Biotechnology industry median Days Payable is 113.76. Bachem Holding AG's value of 24.58 is 78.4% below this industry median. Based on the distribution chart, Bachem Holding AG ranks #543 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bachem Holding AG has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #543 out of 707 companies for Days Payable. This places Bachem Holding AG in the lower half of its industry. The industry median Days Payable is 113.76. Bachem Holding AG's value of 24.58 is 78.4% below this benchmark. Historically, Bachem Holding AG's own Days Payable has ranged from 19.59 to 44.04 over the past decade. While the company's 10-year median is 29.06 vs. the industry median of 113.76, Bachem Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current Days Payable of 24.58 is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bachem Holding AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current Days Payable is 24.58, which is 15% below median its own 10-year median of 29.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.22, compared to a current price of $87.34 — trading 11.1% below its estimated fair value. The current Days Payable is 24.58, which is 15% below median its 10-year median of 29.06 and 78.4% below the Biotechnology industry median of 113.76. Bachem Holding AG's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current Days Payable is 24.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 11.1% below its estimated GF Value™ of $98.22.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
Days Payable: 24.58 (15% below median its 10-year median of 29.06)
GF Value™: $98.22 vs. price of $87.34 (11.1% below fair value)
Industry Position: 78.4% below the Biotechnology median (#543 of 707)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
92GF Score
Get the complete analysis for BCHMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
